Compare IPSC & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | FOCL |
|---|---|---|
| Founded | 2019 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.0M | 222.4M |
| IPO Year | 2021 | 1998 |
| Metric | IPSC | FOCL |
|---|---|---|
| Price | $1.44 | $4.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.75 | ★ $8.80 |
| AVG Volume (30 Days) | ★ 690.4K | 73.4K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,164,000.00 | $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1556.76 | 1.63 |
| 52 Week Low | $0.44 | $4.00 |
| 52 Week High | $2.97 | $6.40 |
| Indicator | IPSC | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 48.98 |
| Support Level | $0.90 | $4.01 |
| Resistance Level | $2.62 | $4.63 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 31.43 | 40.86 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.